This company has been acquired
ImmunoGen (IMGN) Stock Overview
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IMGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
ImmunoGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.23 |
| 52 Week High | US$31.25 |
| 52 Week Low | US$3.61 |
| Beta | 1.17 |
| 1 Month Change | 4.94% |
| 3 Month Change | 98.16% |
| 1 Year Change | 617.93% |
| 3 Year Change | 196.58% |
| 5 Year Change | 452.74% |
| Change since IPO | 228.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.6% | -5.9% | -2.2% |
| 1Y | 617.9% | 34.6% | 13.1% |
Return vs Industry: IMGN exceeded the US Biotechs industry which returned 4% over the past year.
Return vs Market: IMGN exceeded the US Market which returned 20.6% over the past year.
Price Volatility
| IMGN volatility | |
|---|---|
| IMGN Average Weekly Movement | 24.0% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: IMGN's share price has been volatile over the past 3 months.
Volatility Over Time: IMGN's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 277 | Mark Enyedy | www.immunogen.com |
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate.
ImmunoGen, Inc. Fundamentals Summary
| IMGN fundamental statistics | |
|---|---|
| Market cap | US$8.36b |
| Earnings (TTM) | -US$73.52m |
| Revenue (TTM) | US$287.61m |
Is IMGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMGN income statement (TTM) | |
|---|---|
| Revenue | US$287.61m |
| Cost of Revenue | US$211.62m |
| Gross Profit | US$76.00m |
| Other Expenses | US$149.52m |
| Earnings | -US$73.52m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 26.42% |
| Net Profit Margin | -25.56% |
| Debt/Equity Ratio | 12.8% |
How did IMGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/12 04:56 |
| End of Day Share Price | 2024/02/12 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmunoGen, Inc. is covered by 15 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Mara Goldstein | Cantor Fitzgerald & Co. |
| Ling Wang | Chardan Capital Markets, LLC |